Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

475 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Drug-microenvironment perturbations reveal resistance mechanisms and prognostic subgroups in CLL.
Bruch PM, Giles HA, Kolb C, Herbst SA, Becirovic T, Roider T, Lu J, Scheinost S, Wagner L, Huellein J, Berest I, Kriegsmann M, Kriegsmann K, Zgorzelski C, Dreger P, Zaugg JB, Müller-Tidow C, Zenz T, Huber W, Dietrich S. Bruch PM, et al. Among authors: dreger p. Mol Syst Biol. 2022 Aug;18(8):e10855. doi: 10.15252/msb.202110855. Mol Syst Biol. 2022. PMID: 35959629 Free PMC article.
Autologous graft-versus-host disease-like syndrome after an alemtuzumab-containing conditioning regimen and autologous stem cell transplantation for chronic lymphocytic leukemia.
Zenz T, Ritgen M, Dreger P, Kröber A, Barth TF, Schlenk R, Böttcher S, Hallek MJ, Kneba M, Bunjes D, Döhner H, Stilgenbauer S. Zenz T, et al. Among authors: dreger p. Blood. 2006 Sep 15;108(6):2127-30. doi: 10.1182/blood-2006-04-007898. Epub 2006 May 25. Blood. 2006. PMID: 16728696 Free article. Clinical Trial.
Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
Stilgenbauer S, Zenz T, Winkler D, Bühler A, Schlenk RF, Groner S, Busch R, Hensel M, Dührsen U, Finke J, Dreger P, Jäger U, Lengfelder E, Hohloch K, Söling U, Schlag R, Kneba M, Hallek M, Döhner H; German Chronic Lymphocytic Leukemia Study Group. Stilgenbauer S, et al. Among authors: dreger p. J Clin Oncol. 2009 Aug 20;27(24):3994-4001. doi: 10.1200/JCO.2008.21.1128. Epub 2009 Jul 13. J Clin Oncol. 2009. PMID: 19597025 Clinical Trial.
Allogeneic stem cell transplantation provides durable disease control in poor-risk chronic lymphocytic leukemia: long-term clinical and MRD results of the German CLL Study Group CLL3X trial.
Dreger P, Döhner H, Ritgen M, Böttcher S, Busch R, Dietrich S, Bunjes D, Cohen S, Schubert J, Hegenbart U, Beelen D, Zeis M, Stadler M, Hasenkamp J, Uharek L, Scheid C, Humpe A, Zenz T, Winkler D, Hallek M, Kneba M, Schmitz N, Stilgenbauer S; German CLL Study Group. Dreger P, et al. Blood. 2010 Oct 7;116(14):2438-47. doi: 10.1182/blood-2010-03-275420. Epub 2010 Jul 1. Blood. 2010. PMID: 20595516 Free article. Clinical Trial.
Blastic plasmacytoid dendritic cell neoplasia (BPDC) in elderly patients: results of a treatment algorithm employing allogeneic stem cell transplantation with moderately reduced conditioning intensity.
Dietrich S, Andrulis M, Hegenbart U, Schmitt T, Bellos F, Martens UM, Meissner J, Krämer A, Ho AD, Dreger P. Dietrich S, et al. Among authors: dreger p. Biol Blood Marrow Transplant. 2011 Aug;17(8):1250-4. doi: 10.1016/j.bbmt.2010.12.706. Epub 2011 Jan 6. Biol Blood Marrow Transplant. 2011. PMID: 21215813 Free article.
Steroid-refractory GVHD: T-cell attack within a vulnerable endothelial system.
Luft T, Dietrich S, Falk C, Conzelmann M, Hess M, Benner A, Neumann F, Isermann B, Hegenbart U, Ho AD, Dreger P. Luft T, et al. Among authors: dreger p. Blood. 2011 Aug 11;118(6):1685-92. doi: 10.1182/blood-2011-02-334821. Epub 2011 Jun 2. Blood. 2011. PMID: 21636856 Free article.
475 results